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CYTOSTAT IC  GENE TRANSFER FOR 
VASCULAR PROL IFERAT IVE  D ISORDERS 
Clinically significant restenosis remains the major complication of 
all percutaneous coronary revascularization procedures, occurring 
in 30% to 50% of patients within the first 6 months after revascu- 
latization. Although a number of factors contribute to restenosis, 
smooth muscle cell migration and proliferation and extracellular 
matrix deposition appear to be important pathophysiologic mecha- 
nisms. More than 30 different drugs and devices have been used in 
an attempt to prevent restenosis. This presentation utlines recent 
progress in using cytotoxic and cytostatic gene therapy for the 
prevention of restenosis. Recent work suggests that catheter- 
mediated elivery of replication-defective ad noviruses can be used 
to efficiently transduce medial vascular smooth muscle cells 
(VSMCs) after balloon angioplasty. Replication-defective ad novi- 
ruses encoding anonphosphorylatable, constituitively active form 
of the retinoblastoma gene (AdARb) and the herpes implex virus 
thymidine kinase gene (AdvTk) were constructed. Infection of 
primary rat aortic smooth muscle cells with AdARb completely 
inhibited growth factor-stimulated VSMC proliferation i  vitro. 
More importantly, AdkRb infection of balloominjured arterial 
segments reduced restenosis by 50% to 70% in the rat carotid and 
porcine iliofemoral models of balloon angioplasty. Safety studies 
demonstrated (1) no vascular inflammation, (2) no evidence of 
distant infection with AdkRb after local catheter delivery, and (3) 
no significant abnormalities of serum chemical composition or 
clotting parameters. Finally, infection with AdARb did not inhibit 
reendothelialization of the balloon-injured vessels. In a parallel set 
of experiments, infection of primary rat aortic smooth muscle cells 
with the AdvTK vector followed by ganciclovir treatment resulted 
in the efficient killing of proliferating cultured vascular smooth 
muscle cells in vitro. More importantly, infection with this vector 
followed by systemic ganciclovir t eatment resulted in 50% to 70% 
reductions in restenosis in both the rat carotid and porcine 
iliofemoral artery models of balloon angioplasty. There were no 
local or systemic toxicities associated with AdvTk plus ganciclovir 
therapy. In summary, catheter-mediated delivery of adenovirus 
vectors represents an efficient means of delivering recombinant 
genes to vascular smooth muscle cells at the site of balloon 
angioplasty. Both cytotoxic and cytostatic genes have been used to 
significantly reduce restenosis in two animal models of balloon 
angioplasty. Gene therapy holds promise as a safe and effective 
means of inhibiting restenosis after balloon angioplasty and other 
percutaneous revascularization procedures in human beings. 
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MODIF ICAT ION OF  THE VASCULAR 
PHENOTYPE BY V IRAL  GENE TRANSFER:  
THERAPY AND TOXIC ITY  
Genetic modification of the vessel wall holds promise for the study 
of vascular pathophysiology and for the therapy of vascular disease. 
Using a variety of techniques, including viral and liposome- 
mediated gene transfer, specific genes may be introduced into 
vascular smooth muscle cells or endothelial cells to modify the 
vascular phenotype. Eventually such an approach may be clinically 
applied to artery or vein grafts, mechanically denuded vessels, or 
prosthetic grafts in the operative setting to prevent hrombosis, 
